125320-20-9

Upstream product

• 139706-48-2 4-(tert-butyldimethylsilyloxymethyl)benzoic acid methyl ester 
• 6908-41-4 4-(methoxycarbonyl)benzyl alcohol 
• 544-00-3 3-methyl-N-(3-methylbutyl)-1-butanamine 
• 71831-21-5 4-(bromomethyl)benzyl alcohol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 589-29-7 p-xylylene glycol 
• 118992-89-5 [4-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl]methanol 

Downstream Products

• 204507-41-5 3-[4-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-2-{2-[1-methoxy-meth-(Z)-ylidene]-cyclohexylmethyl}-propionitrile 
• 900183-42-8 4-((2R)-2-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)benzyl]oxy}propanoyl)morpholine 
• 1323404-89-2 3-[4-[[4-(hydroxymethyl)phenyl]methoxy]-1-oxoisoindolin-2-yl]piperidine-2,6-dione 
• 1058178-90-7 N-[4-[[4-(tert-butyldimethylsilyloxymethyl)benzyl](4-nitrophenyl)amino]-1-methylpyrrole-2-carbonyl]pyrrolidine 
• 137420-74-7 3-(4-t-butyldimethylsilyloxymethyl)phenyl-2-phenylpropionitrile 
• 204507-42-6 4-[4-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-3-{2-[1-methoxy-meth-(Z)-ylidene]-cyclohexylmethyl}-butan-2-one 
• 808132-60-7 4-{2-[5-((2E,4E)-2,5-Dimethyl-nona-2,4-dienoyl)-4-hydroxy-6-oxo-6H-pyran-2-yl]-propyl}-benzoic acid methyl ester 
• 808132-24-3 4-[2-(4-hydroxy-6-oxo-5-propionyl-6H-pyran-2-yl)-propyl]-benzoic acid methyl ester 
• 808132-56-1 4-hydroxy-6-[2-(4-hydroxymethyl-phenyl)-1-methyl-ethyl]-3-propionyl-pyran-2-one 
• 808132-58-3 4-[2-(4-hydroxy-6-oxo-5-propionyl-6H-pyran-2-yl)-propyl]-benzaldehyde 

Relevant academic research and scientific papers

Rational Design of Vitamin D3 Analogues Which Selectively Restore Activity to a Vitamin D Receptor Mutant Associated with Rickets

(Matrix Presented) Vitamin D3-resistant rickets (VDRR) is associated with mutations to the Vitamin D receptor (VDR) which effect ligand-dependent transactivation. Some VDRR associated mutants directly disrupt ligand binding. Using the reported

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE

Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral E1A binding protein of 300kDa (P300) ligand (CBP/P300 ligand) conjugated

Synthesis of heterosubstituted hexaarylbenzenes via asymmetric carbonylative couplings of benzyl halides

Asymmetric carbonylative couplings of benzyl halldes have been shown to give heterosubstituted 1,3-diarylacetones In moderate to high yields. These asymmetric ketones were converted via Knoevenagel condensations to tetraarylcyclopentadienones, and further

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl.

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. (1) wherein: the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl, etc.

Cryptophycin compounds

The present invention provides cryptophycin compounds of Formula I that are useful in the treatment of neoplasms.

Design, synthesis, derivatization, and structure-activity relationships of simplified, tricyclic, 1,2,4-trioxane alcohol analogues of the antimalarial artemisinin

Novel C4-(hydroxyalkyl)trioxanes 5d and 5e were designed and synthesized based on an understanding of the molecular mechanism of action of similar 1,2,4-trioxanes structurally related to the antimalarial natural product artemisinin (1). In vitr

Imidazole angiotensin II antagonists incorporating a substituted benzyl element

Substituted imidazoles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I, are useful as angiotensin II antagonists. STR1